Identifying Good Candidates for Active Surveillance of Ductal Carcinoma <i>In Situ</i> : Insights from a Large Neoadjuvant Endocrine Therapy Cohort

Alexa Glencer(University of California, San Francisco), Laura J. Esserman(University of California, San Francisco)

Cancer Research Communications

November 21, 2022

10.1158/2767-9764.crc-22-0263

Cited by 13

Related Papers

Whole-genome analysis informs breast cancer response to aromatase inhibition

|Nature|2012|1k

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer

|JAMA Oncology|2020|707

Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL

|Radiology|2012|487

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

|Journal of Clinical Oncology|2017|411

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

|Cancer Cell|2022|335